File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies

TitleThe association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies
Authors
KeywordsDabigatran
Gastrointestinal bleeding
Real‐life
Rivaroxaban
Issue Date2016
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125
Citation
British Journal of Clinical Pharmacology, 2016, v. 82 n. 1, p. 285-300 How to Cite?
AbstractParticular concerns have been raised regarding the association between non‐vitamin K antagonist oral anticoagulants (NOACs) and the risk of gastrointestinal bleeding (GIB); however, current findings are still inconclusive. We conducted a systematic review with a meta‐analysis to examine the association between NOACs and GIB in real‐life settings. We performed a systematic search of PubMed, EMBASE and CINAHL Plus up to September 2015. Observational studies that evaluated exposure to NOACs reporting GIB outcomes were included. The inverse variance method using the random‐effects model was used to calculate the pooled estimates. Eight cohort studies were included in the primary meta‐analysis, enrolling 1442 GIB cases among 106 626 dabigatran users (49 486 patient‐years), and 184 GIB cases among 10 713 rivaroxaban users (4046 patient‐years). The pooled incidence rates of GIB were 4.50 [95% confidence interval (CI) 3.17, 5.84] and 7.18 (95% CI 2.42, 12.0) per 100 patient‐years among dabigatran and rivaroxaban users, respectively. The summary risk ratio (RR) was 1.21 (95% CI 1.05, 1.39) for dabigatran compared with warfarin, and 1.09 (95% CI 0.92, 1.30) for rivaroxaban. Subgroup analyses showed a dose‐related effect of dabigatran, with a significantly higher risk of GIB for 150 mg b.i.d. (RR = 1.51, 95% CI 1.34, 1.70) but not for 75 mg b.i.d. or 110 mg b.i.d.. In addition, the use of proton pump inhibitors (PPIs)/histamine H2‐receptor antagonists (H2RAs) influenced the association in dabigatran users, whereas this effect was modest among rivaroxaban users. In conclusion, our meta‐analysis suggested a slightly higher risk of GIB with dabigatran use compared with warfarin, whereas no significant difference was found between rivaroxaban and warfarin for GIB risk.
Persistent Identifierhttp://hdl.handle.net/10722/229287
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 1.046
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHe, YH-
dc.contributor.authorWong, ICK-
dc.contributor.authorLi, X-
dc.contributor.authorAnand, S-
dc.contributor.authorLeung, WK-
dc.contributor.authorSiu, DCW-
dc.contributor.authorChan, EW-
dc.date.accessioned2016-08-23T14:10:09Z-
dc.date.available2016-08-23T14:10:09Z-
dc.date.issued2016-
dc.identifier.citationBritish Journal of Clinical Pharmacology, 2016, v. 82 n. 1, p. 285-300-
dc.identifier.issn0306-5251-
dc.identifier.urihttp://hdl.handle.net/10722/229287-
dc.description.abstractParticular concerns have been raised regarding the association between non‐vitamin K antagonist oral anticoagulants (NOACs) and the risk of gastrointestinal bleeding (GIB); however, current findings are still inconclusive. We conducted a systematic review with a meta‐analysis to examine the association between NOACs and GIB in real‐life settings. We performed a systematic search of PubMed, EMBASE and CINAHL Plus up to September 2015. Observational studies that evaluated exposure to NOACs reporting GIB outcomes were included. The inverse variance method using the random‐effects model was used to calculate the pooled estimates. Eight cohort studies were included in the primary meta‐analysis, enrolling 1442 GIB cases among 106 626 dabigatran users (49 486 patient‐years), and 184 GIB cases among 10 713 rivaroxaban users (4046 patient‐years). The pooled incidence rates of GIB were 4.50 [95% confidence interval (CI) 3.17, 5.84] and 7.18 (95% CI 2.42, 12.0) per 100 patient‐years among dabigatran and rivaroxaban users, respectively. The summary risk ratio (RR) was 1.21 (95% CI 1.05, 1.39) for dabigatran compared with warfarin, and 1.09 (95% CI 0.92, 1.30) for rivaroxaban. Subgroup analyses showed a dose‐related effect of dabigatran, with a significantly higher risk of GIB for 150 mg b.i.d. (RR = 1.51, 95% CI 1.34, 1.70) but not for 75 mg b.i.d. or 110 mg b.i.d.. In addition, the use of proton pump inhibitors (PPIs)/histamine H2‐receptor antagonists (H2RAs) influenced the association in dabigatran users, whereas this effect was modest among rivaroxaban users. In conclusion, our meta‐analysis suggested a slightly higher risk of GIB with dabigatran use compared with warfarin, whereas no significant difference was found between rivaroxaban and warfarin for GIB risk.-
dc.languageeng-
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125-
dc.relation.ispartofBritish Journal of Clinical Pharmacology-
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectDabigatran-
dc.subjectGastrointestinal bleeding-
dc.subjectReal‐life-
dc.subjectRivaroxaban-
dc.titleThe association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies-
dc.typeArticle-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailLi, X: sxueli@hku.hk-
dc.identifier.emailAnand, S: shweta@hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityLi, X=rp02531-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.authoritySiu, DCW=rp00534-
dc.identifier.authorityChan, EW=rp01587-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bcp.12911-
dc.identifier.pmid26889922-
dc.identifier.pmcidPMC4917795-
dc.identifier.scopuseid_2-s2.0-84976558031-
dc.identifier.hkuros260111-
dc.identifier.hkuros263880-
dc.identifier.volume82-
dc.identifier.issue1-
dc.identifier.spage285-
dc.identifier.epage300-
dc.identifier.isiWOS:000382508900027-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0306-5251-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats